lupus.bmj21h
LBO1 DORIS remission in patients with SLE treated with anifrolumab or placebo during the 4-year TULIP-LTE trial: post hoc analysis
3 Division of Rheumatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, USA 4 Division of Rheumatology, Allergy and Immunology, University of California San ...
lupus.bmj1d
Systemic lupus erythematosus complicated by diffuse alveolar haemorrhage: risk factors, therapy and survival
Objectives While diffuse alveolar haemorrhage (DAH) is recognised as a life-threatening complication of systemic lupus erythematosus (SLE), little is known about its risk factors and response to ...